Salivary and lacrimal disorders in patients treated with radioiodine for differentiated thyroid cancer
Authors' conclusion
This systematic review and meta-analysis highlighted the frequency and persistence of salivary and lacrimal dysfunctions following RIT.
Study context
- Population
- Patients treated with RAI for differentiated thyroid cancer (DTC)38 studies
- Outcome
- Prevalence and characteristics of salivary and lacrimal dysfunctions
Methodological detailsPRISMA guidelines, random-effects models, PubMed and Scopus, 2000–2024
- PRISMA guidelines
- Random-effects models
- PubMed and Scopus, 2000–2024
Pooled result
As reported in the abstract
Pooled prevalence of xerostomia
Xerostomia at <2 months post-RIT
60%
95% CI 0.28–0.85
Xerostomia at more than 1 year post-RIT
17%
95% CI 0.10–0.28
Further pooled results
Administered I131 activity and xerostomia
- Significant association between high administered I131 activity (study-specific thresholds) and xerostomia
Sialadenitis and lacrimal dysfunctions
- Sialadenitis and lacrimal dysfunctions also frequently reported
- Most studies highlighted frequently persistent impairment in many patients
- Heterogeneity in protocols and assessment tools
Original publication
Salivary and lacrimal disorders in patients treated with radioiodine for differentiated thyroid cancer. Eur Thyroid J. Published 22 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →